Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioRestorative Therapies (BRTX) Operating Expenses (2016 - 2025)

Historic Operating Expenses for BioRestorative Therapies (BRTX) over the last 15 years, with Q3 2025 value amounting to $3.7 million.

  • BioRestorative Therapies' Operating Expenses rose 4827.03% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.9 million, marking a year-over-year increase of 1955.16%. This contributed to the annual value of $11.9 million for FY2024, which is 2237.62% down from last year.
  • As of Q3 2025, BioRestorative Therapies' Operating Expenses stood at $3.7 million, which was up 4827.03% from $3.6 million recorded in Q2 2025.
  • In the past 5 years, BioRestorative Therapies' Operating Expenses registered a high of $15.1 million during Q1 2021, and its lowest value of $2.5 million during Q3 2024.
  • Moreover, its 5-year median value for Operating Expenses was $3.7 million (2025), whereas its average is $4.5 million.
  • Per our database at Business Quant, BioRestorative Therapies' Operating Expenses skyrocketed by 168376.95% in 2021 and then plummeted by 6636.43% in 2022.
  • BioRestorative Therapies' Operating Expenses (Quarter) stood at $4.0 million in 2021, then increased by 16.72% to $4.7 million in 2022, then plummeted by 30.85% to $3.2 million in 2023, then decreased by 15.74% to $2.7 million in 2024, then surged by 35.9% to $3.7 million in 2025.
  • Its last three reported values are $3.7 million in Q3 2025, $3.6 million for Q2 2025, and $4.8 million during Q1 2025.